Furthermore, the co-administration of ML385, an Nrf2 pathway inhibitor, nearly abolished the protective effects of GRN at both doses (H + M + G10 vs. H, p > 0.05; H + M + G30 vs. H, p > 0.05), indicating that the neuroprotective effects of GRN against HPD-induced orofacial dyskinesia are mediated via the Nrf2 signaling pathway. Here, NFE2L2 is linked to Orofacial dyskinesia.